Letter: Implementation of a Long-Acting Injectable Program for HIV Prevention and Treatment in Adolescents and Young Adults: Insights from a Northeastern US Program

Center for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2021. Center for Disease Control and Prevention: Atlanta, GA; 2023.

U.S. Food and Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. Silver Springs, MD; 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention#:∼:text=Today%2C%20the%20U.S.%20Food%20and%20Drug%20Administration%20approved,to%20reduce%20the%20risk%20of%20sexually%20acquired%20HIV [Last accessed: July 1, 2024].

U.S. Food and Drug Administration. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. Silver Springs, MD; 2021. Available from: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection [Last accessed: July 1, 2024].

Barfield A , Ohene-Kyei ET , Smith R , et al. Exploring preferences, concerns, and implementation of different long-acting antiretroviral strategies for youth with HIV facing adherence challenges. AIDS Patient Care STDS, 2025; 39(7):289–295; doi: 10.1089/apc.2025.0039

Fisk-Hoffman RJ , Ranger SS , Gracy A , et al. Perspectives among health care providers and people with HIV on the implementation of long-acting injectable cabotegravir/rilpivirine for antiretroviral therapy in Florida. AIDS Patient Care STDS, 2024; 38(6):275–285; doi: 10.1089/apc.2024.0067

Czarnogorski M , Garris CP , Dalessandro M , et al. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE). J Int AIDS Soc, 2022; 25(9):e26003; doi: 10.1002/jia2.26003

Patel RR , Mayer KH . Why is roll-out of long-acting PrEP agents so slow? Curr Opin HIV AIDS, 2025; 20(1):48–53; doi: 10.1097/COH.0000000000000899

Williams T , Unternaher J , Koay WLA , et al. Efficacy, safety and retention in care among adolescents and youth with HIV on long-acting injectable cabotegravir/rilpivirine treatment: Real-world observational cohort outcomes. Pediatr Infect Dis J, 2025; 44(7):650–656; doi: 10.1097/INF.0000000000004742

Mayer K , Brown C , Frick A , et al. Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Trio Health Cohort. International Antiviral Society–USA: Denver, CO; 2024.

Eron JJ , Sarkar S , Frick AJ , et al. Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data from Trio Health Cohort. International Antiviral Society–USA: Denver, CO; 2024.

Weiner BJ , Lewis CC , Stanick C , et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci, 2017; 12(1):108; doi: 10.1186/s13012-017-0635-3

Hosek SG , Landovitz RJ , Kapogiannis B , et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr, 2017; 171(11):1063–1071; doi: 10.1001/jamapediatrics.2017.2007